A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas


Disclosures: NCI-CTEP U01 Grant Program at MDACC, Celgene, Millennium/Takeda, and National Stem Cell Foundation

Contributions: MAF designed the study, analyzed the data, provided clinical care to patients, and wrote the paper; PS analyzed data and wrote the paper; RP designed the study and coauthored the paper; LEF, LN, RED, NF, FH, LK, HL, YO, MW and JW provided clinical care to patients and coauthored the paper; ETW and CER collected the data and coauthored the paper.